Skip to content

Syntis is advancing a pipeline of proprietary programs




  • Daily oral pill that blocks duodenal nutrient absorption
  • Same mechanism leveraged by Gastric Bypass Surgery
  • Favorable tolerability & cost profile over GLP-1 drugs
FIH Studies


MGL Enzyme

  • Proprietary MGL (Methionine-gamma-lyase) eliminates dietary Methionine (Met)
  • Engineered for activity throughout the GI tract
  • Designed to control Met & tHcy levels, reduce dietary restrictions
INDE Studies


GI-Stable MGL

  • Proprietary MGL w/ DIGEST™ Extended Delivery
  • Sustained duodenal activity targets dietary & enteroenterically recirculated Met
  • Maximum Met & tHcy control, maximum dietary freedom
Maple Syrup Urine Disease


LDC Enzyme

  • Proprietary LDC (Leucine Decarboxylase) eliminates dietary Leucine
  • Engineered for activity throughout the GI tract
  • Designed to control Leucine (Leu) levels, reduce dietary restrictions
INDE Studies


GI-Stable LDC

  • Proprietary LDC w/ DIGEST™ Extended Delivery
  • Sustained duodenal activity targets dietary & enteric recirculated Leu
  • Maximum Leu control, maximum dietary freedom

SYNT-101: Obesity

Obesity is a global epidemic, impacting 100 million people in the U.S. and 800 million worldwide—with the latter figure projected to reach 1.5 billion by 2030.

GLP-1 drugs have achieved unprecedented weight loss efficacy and created new hope for patients living with obesity and related conditions. Issues related to accessibility, cost, tolerability and long-term therapeutic maintenance persist, however, creating growing demand for more diverse solutions. Our lead candidate, SYNT-101, may offer an alternative and/or complementary approach intended to provide patients with a more affordable and sustainable path forward.

SYNT-101 is an investigational obesity treatment designed to mimic the effects of gastric bypass surgery by transiently blocking nutrient absorption in the small intestine – all within the convenience of a once-daily pill.

SYNT-101 leverages our BARRIER™ platform, powered by SYNT™ (SYNthetic Tissue-lining) technology, to deliver an absorption-blocking polydopamine lining precisely to the upper part of the small intestine, called the duodenum, for up to 24 hours after which it is naturally and safely cleared from the body. This mechanism, known as duodenal nutrient exclusion, diverts nutrients to the lower small intestine (the jejunum and ileum) where absorption is more controlled and stimulates a full cascade of endogenous satiety hormones such as GLP-1 and PYY.  

An investigational formulation of SYNT-101 is currently undergoing human trials to establish preliminary safety, tolerability and blocking efficacy, with data anticipated by the end of 2024. We believe that SYNT-101 has the potential to achieve significant, sustainable weight loss at a more favorable cost and tolerability profile than existing injectable GLP-1 therapies.

Pediatric Rare Disease Portfolio

We are also developing a portfolio of gut-restricted enzyme replacement therapies to address rare metabolic disorders that lack approved treatments.

Our two leading enzyme programs are indicated in orphan pediatric diseases Homocystinuria (SYNT-202) and maple syrup urine disease (SYNT-203). SYNT-202 and SYNT-203 were acquired from Codexis, Inc. in 2024 after eight years of optimization for GI stability through Codexis’ groundbreaking CodeEvolver™ platform that discovers and develops novel, high-performance enzymes. SYNT-202 and SYNT-203 have completed non-human primate studies and are progressing toward IND-enabling studies. Next-generation versions of these programs are also in development, which leverage the DIGEST™ platform to sustain gut-restricted activity for maximum disease control (SYNT-212 and SYNT-213).